Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (KVUE) reports developments as a pure-play consumer health company with a brand portfolio that includes Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its updates center on consumer health categories, operating and financial results, and board actions such as cash dividends on common stock.
Recurring news themes also include material agreements, capital-structure matters, governance changes, shareholder voting topics and consumer-health regulatory disclosures. The coverage reflects Kenvue’s role as a public company operating branded everyday-care products across personal care, oral care, pain management and related health categories.
Kimberly-Clark (NASDAQ: KMB) and Kenvue (NYSE: KVUE) reported that shareholders at special meetings overwhelmingly approved the proposed acquisition of Kenvue by Kimberly-Clark.
Preliminary voting showed ~96% of shares at Kimberly-Clark approved issuance of Kimberly-Clark stock and ~99% of votes at Kenvue adopted the merger agreement (about 77% of outstanding Kenvue shares). The transaction is expected to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
Kenvue (NYSE: KVUE) declared a quarterly cash dividend of $0.2075 per share. The dividend is payable on February 25, 2026 to shareholders of record at the close of business on February 11, 2026. This is a regular cash distribution on common stock.
The announcement lists investor and media contacts and describes Kenvue as a consumer health company with brands such as Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena and Tylenol.
Summary not available.
Kimberly-Clark (NASDAQ: KMB) agreed to acquire Kenvue (NYSE: KVUE) in a cash-and-stock transaction valuing Kenvue at an enterprise value of approximately $48.7 billion (based on KMB close on Oct 31, 2025). The deal offers Kenvue shareholders $3.50 cash plus 0.14625 KMB shares (total $21.01 per KVUE share) and is expected to close in H2 2026, subject to approvals.
The combined company is projected to generate ~$32 billion revenue and ~$7 billion adjusted EBITDA in 2025, with anticipated run-rate synergies of $2.1 billion and $2.5 billion of one-time costs to capture them. Post-close ownership: ~54% KMB / 46% KVUE.
Kenvue (NYSE: KVUE) declared a quarterly cash dividend of $0.2075 per share. The dividend is payable on November 26, 2025 to shareholders of record as of the close of business on November 12, 2025. The announcement provides a dated cash return to shareholders and specifies payment and record dates.
Contact details for investor and media relations were provided.
Kenvue (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025.
The company will host a conference call and live webcast at 8:30 a.m. ET; U.S. dial-in 877-407-8835, international dial-in +1 201-689-8779. A replay will be available after the live event at investors.kenvue.com.
Contact details provided for investor and media relations. Kenvue is described as a global consumer health company with brands including Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol.
Albert Invent announced a strategic, multi-year partnership with Kenvue (NYSE: KVUE) to accelerate end-to-end R&D across Kenvue's global consumer health brands. The collaboration began in Q1 2025 and focuses on integrating Albert Invent's AI platform to digitalize workflows, unify data management, and automate hundreds of R&D processes.
Albert Invent's proprietary engine is trained on over 15 million molecular structures and is used by thousands of researchers in 30+ countries. The partnership aims to speed product development, improve quality control, and streamline regulatory compliance across Kenvue's brands.
Kenvue (NYSE: KVUE) reported challenging Q2 2025 results with declining performance across key metrics. Net sales decreased 4.0% year-over-year, with organic sales declining 4.2%. The company reported diluted EPS of $0.22 and adjusted diluted EPS of $0.29, down from $0.32 in the prior year.
Under new leadership, including Interim CEO Kirk Perry and CFO Amit Banati, Kenvue revised its FY2025 outlook downward, now expecting low-single-digit declines in net and organic sales, with adjusted diluted EPS projected at $1.00-$1.05. The company is advancing a comprehensive strategic alternatives review while implementing measures to accelerate profitable growth.
The performance decline was attributed to unfavorable value realization of 0.9%, volume decline of 3.3%, weak seasonal performance in North America, and trade inventory fluctuations. The company's gross profit margin contracted to 58.9% from 59.1% year-over-year.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, has announced a dividend increase. The company's Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, representing a 1.2% increase from the previous quarter.
The dividend will be payable on August 27, 2025, to shareholders of record as of August 13, 2025. Kenvue's portfolio includes well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, will release its Q2 2025 financial results before market open on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results.
Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event.